Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (October 2025)
56 slides from Inoviq's investor presentation, Oct 13, 2025
Slide 1: INOVIQ overview
INOVIQ overview Next-generation cancer diagnostics and therapeutics October 2025 Capital Raise ASX: IIQ
Slide 2: Contents
Contents Important Notice & Disclaimer p3 INOVIQ Overview p4 Exosome Diagnostics p9 Exosome Therapeutics p16 Exosome Research Tools p24 SubB2M Cancer Diagnostics p28 Catalysts & Transaction Summary p34 Appendices & Risks p41 2
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer The following notice and disclaimer applies to this investor presentation (Presentation or document) and you are therefore advised to read this carefully Regulatory Guide 230 Disclosing non-IFRS financial information published by ASIC and also "non-GAAP financial measur
Slide 4: INOVIQ Overview
INOVIQ Overview| Next-generation diagnostics and therapeutics for cancer Financial snapshot (ASX:IIQ) Market capitalisation A$46.3m Proprietary exosome platform with multiple research, diagnostic and therapeutic applications Share price (8 October 2025) A$0.415 52-week H/L A$0.690-0.345 Exosome rese
Slide 5: What are exosomes and how are they revolutionizing health care?
What are exosomes and how are they revolutionizing health care? • Cells release EVs (including exosomes) that carry information from their parent cell • These EVs can interact with other cells, transferring this information to change the cell’s behaviour • INOVIQ’s proprietary technology leverages t
Slide 6: Achievements & Catalysts
Achievements & Catalysts| Building a leading exosome company FY25 Achievements FY26 Catalysts 3-Year Objectives Partner diagnostic programs, INOVIQ established as a Expand exosome platform accelerate development of leading exosome company across research tools, exosome therapeutics and with best-in-
Slide 7: Strategic pillars
Strategic pillars| Driving growth and value across diagnostics & therapeutics 1 Exosome platform 2 Research tools 3 Diagnostics 4 Therapeutics Proprietary exosome Exosome isolation Exosome tests for Exosome therapeutics technology platform tools for biomarker screening, liquid to target and destroy
Slide 8: Products & pipeline
Products & pipeline| Staged research tools, diagnostics & therapeutics portfolio • Product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a preclinical-stage CAR-exosome therapeutic program for solid tumours • Pipeline p
Slide 9: Exosome Diagnostics
Exosome Diagnostics Next-gen liquid biopsies and companion diagnostics 9
Slide 10: Ovarian Cancer screening is a significant unmet need
Ovarian Cancer screening is a significant unmet need Deadliest gynaecological cancer & 8th most 5-Year Survival following Diagnosis (UK)3 #1 common cancer in women 100% 95% 80% 60% 70% 325k New cases pa1 ~70% diagnosed at stage III or IV4 no approved 40% 45% test for early 20% 30% detection in asymp
Slide 11: Ovarian Cancer in Major Markets
Ovarian Cancer in 9 Major Markets Market Incidence Prevalence Eligible Population General Annual 1 (5-year) (45-74yo) Screening Addressable 11 Participation Population 2 China 61,060 180,870 282,713,102 51.4% 145,201,449 3 USA 21,179 68,388 60,689,385 75.7% 45,941,864 4 Japan 10,693 33,732 24,907,72
Slide 12: EXO-OC | Ovarian cancer screening test
EXO-OC | Ovarian cancer screening test • Exosome diagnostic test developed in a collaboration between INOVIQ and UQ1 • Poster presented and published at ASCO 2025 titled Early detection of ovarian cancer: An accurate high-throughput extracellular vesicle test2 • Proprietary EXO-NET® technology used
Slide 13: EXO-OC | Multimarker miRNA validation study
EXO-OC | Multimarker miRNA validation study Study Design: Retrospective case-control study (n=498)1 • Biobanked plasma samples from age-matched normal healthy Percent of Samples Correctly Identified by EXO-OC women and benign masses vs ovarian cancers (stage I – IV) • Proprietary machine learning al
Slide 14: EXO-OC | Development & commercialisation roadmap
EXO-OC | Development & commercialisation roadmap Clinical & Regulatory Advice underway Multi-stage commercialisation strategy to ensure the rapid and 2025 broad availability of the EXO-OC test to women worldwide Partnering with high-complexity CLIA lab • Expanded analytical and clinical validation s
Slide 15: EXO-OC | Planned model validation studies
EXO-OC | Planned model validation studies Subject Details Group Samples Percent Percent Total Cancers Single-site, retrospective case-control blinded evaluation study to Healthy Controls 1400 69% Study Design confirm the performance of the EXO-OC test in 2040 plasma samples with performance compared
Slide 16: Diagnostic Deals
Diagnostic Deals| Liquid biopsy platforms Upfront Milestones Total Deal Value Acquiror / Licensee Target / Licensor Date Deal Type Stage Technology (US$m) (US$m) (US$m) Blood-based colorectal cancer screening assay, 1 2025 Exclusive Licence, US FDA Approval Pending $75 $700 $885 detects methylation
Slide 17: Exosome Therapeutics
Exosome Therapeutics Next-gen cell-free therapy to target and kill solid tumours 17
Slide 18: CAR-Exosomes | Next-gen, cell-free therapy for solid tumours
CAR-Exosomes| Next-gen, cell-free therapy for solid tumours • INOVIQ is developing next-gen CAR-exosome therapy, engineered to precisely target and destroy solid tumours • Exosomes mediate the therapeutic effects of cell therapies by interacting directly with target tumour cells • Exosomes derived f
Slide 19: CAR-Exosomes | Cost-effective process compared to Cell Therapy
CAR-Exosomes| Cost-effective process compared to Cell Therapy Cell Therapy next generation CAR-EV NK Therapy Centralised GMP Manufacturing Facility Reprogram to kill Grow enough cells for a cancer cells treatment dose Natural killer cell Reprogram exosome Immortalized cell bank Grow - unlimited Coll
Slide 20: Triple Negative Breast Cancer | Unmet need for effective targeted therapies
Triple Negative Breast Cancer | Unmet need for effective targeted therapies Percent of BC by Subtype4 2.3m Breast Cancer new cases pa1 HR-/HER2+ Unknown 4% 6% HR+/HER2+ 9% HR-/HER2- TNBC 15% TNBC is 10-15% of all breast cancer cases4 11% HR+/HER2- ~20% in women of 70% limited availability African an
Slide 21: Breast Cancer in 9 Major Markets
Breast Cancer in 9 Major Markets| TNBC ~15% of cases Market Incidence Prevalence TNBC 1,2 3 (5-year) incidence USA 274,375 1,194,271 179,141 China 357,161 1,160,496 174,074 Japan 91,916 389,650 58,448 Germany 74,016 313,465 47,020 France 65,659 271,977 40,797 UK 58,756 253,839 38,076 Italy 57,480 23
Slide 22: CAR-Exosomes | Targeted therapy for Triple-Negative Breast Cancer
CAR-Exosomes| Targeted therapy for Triple-Negative Breast Cancer • Lacks key targets: TNBC does not express ER, PR or HER2, making it unresponsive to hormone or HER2-targeted In Vitro effect of CAR-NK-EVs on cell viability in TNBC cells therapies untreated • Limited treatment options: Chemotherapy (
Slide 23: CAR-Exosomes | Therapeutic development path
CAR-Exosomes| Therapeutic development path EXO-ACE In Vivo CRO First Patient CAR EV Isolation Studies Selection Dose CAR-T / NK Cell In Vitro IND IND Approval and Development Studies Submission Site Selection ✓Master cell banks ✓High purity & ✓In vitro PoC for CAR- ❑ Preclinical in established yield
Slide 24: Therapeutic Deals
Therapeutic Deals| Exosome & cell therapies Upfront Milestones Total Deal Value Acquirer / Licensee Target / Licensor Date Deal Type Stage Cell Source (US$m) (US$m) (US$m) 1 2025 Acquisition Phase 1 $350 $0 $350 in vivo CAR 2 2025 Acquisition Phase 1 $2,100 $0 $2,100 in vivo CAR 3 2025 Acquisition P
Slide 25: Exosome Isolation Tools
Exosome Isolation Tools Best-in-class immuno-affinity EV isolation 25
Slide 26: EXO-NET | Pan-exosome isolation product in-market and generating revenue
EXO-NET®| Pan-exosome isolation product in-market and generating revenue Best-in-class EXO-NET pan-exosome capture tool (research use only) surface antigens Enables biomarker discovery and diagnostic development for screening, liquid biopsies and companion diagnostics exosome Offers speed, efficienc
Slide 27: EXO-NET | Promega Corporation - our global distribution partner
EXO-NET| Promega Corporation - our global distribution partner • Promega Early Access Program building traction ahead of full launch, developing the Customer Acquisition market across multiple customer and geographic segments 80 Under Promega Early Access Program incl. 6 repeat • Multiple applicatio
Slide 28: EXO-NET | Research tools and services
EXO-NET®| Research tools and services EXO-NET PAN- CUSTOMISED EXOSOME BIOMARKER DIAGNOSTICS EXOSOME CAPTURE EXO-NET TOOLS ISOLATION DISCOVERY DEVELOPMENT EXO-NET is a research Design custom EV isolation using Biomarker discovery EV-based clinical tool for fast, efficient & EXO-NET tools using EXO-NE
Slide 29: SubB2M Cancer Diagnostics
SubB2M Cancer Diagnostics Improved cancer detection and monitoring neuraminic acid (neu5Gc) 29
Slide 30: SubB2M Technology | Glycan-binding technology and scientific rationale
SubB2M Technology| Glycan-binding technology and scientific rationale Aberrant glycosylation (production of sugars) is a hallmark of cancer Neu5Gc is a sugar commonly found on cancer cells, but not healthy cells SubB2M is an engineered protein that specifically binds neu5Gc SubB2M is used in an immu
Slide 31: Breast Cancer monitoring | unmet need for detecting earlier recurrence
Breast Cancer monitoring| unmet need for detecting earlier recurrence 5-Year Survival following Diagnosis (UK)4 #1 Most common & deadliest cancer in women1 100% 100% 80% 90% 92% 60% 70% non-invasive, 2.3m New cases pa1 40% earlier and more 20% 25% accurate tests 0% required for 666k Deaths pa1 Stage
Slide 32: Breast Cancer in Major Markets | Monitoring opportunity
Breast Cancer in 9 Major Markets| Monitoring opportunity Market Incidence1 Prevalence # Women with MBC Monitoring 1 (5-year) Metastatic BC (MBC) (4x per year)8 2 USA 274,375 1,194,271 140,230 560,920 3 China 357,161 1,160,496 191,319 765,275 3 Japan 91,916 389,650 64,237 256,950 3 Germany 74,016 313
Slide 33: neuCA15-3 clinical data | Outperforms Roche CA15-3 II test
neuCA15-3 clinical data| Outperforms Roche CA15-3 II test Clinical Validation Study by Stage (2023)1 SubB2M CA15-3 vs Leading Existing Test Retrospective, case-control, clinical validation study (n=483) to Breast Cancer SubB2M Roche evaluate breast cancer detection by stage All Stages CA15-3 Elecsys
Slide 34: neuCA15-3 | Development & commercialisation roadmap
neuCA15-3| Development & commercialisation roadmap1 Intended Use •Aid in the monitoring of breast cancer Assay •Technology transfer underway to bead-based assay compatible with an automated instrument platform to facilitate scalability & Development partnering discussions Verification •Additional st
Slide 35: Catalysts & Transaction Summary
Catalysts & Transaction Summary 35
Slide 36: Future Catalysts
Future Catalysts| Driving growth and value across our pipeline Jul-25 Dec-25 Jun-26 EXO-OC • Commence clinical validation for OC • Strategic partnering for LDT (OC screening) screening commercialisation • Progress IVD clinical & regulatory strategy CAR-Exosome • In vivo efficacy data in TNBC model •
Slide 37: Summary
Summary| Positioned for growth Leading exosome company Exosome research tools Clinical-stage EXO-OC with proven technology partnered, on-market and screening test targeting platform and best-in-class generating initial revenue significant unmet need in research tools, diagnostics with potential for
Slide 38: Capital Raising Overview
Capital Raising Overview • Capital raising of A$11.5m at $0.35 per share, consisting of an A$9.5m Placement and A$2m Share Purchase Plan (SPP) with IIQ Board Overview discretion to accept oversubscriptions • The Company has raised A$9.5 million via a placement to institutional, sophisticated and pro
Slide 39: Use of Funds
Use of Funds Funds raised will be used to: • Accelerate clinical validation and LDT commercialisation of INOVIQ's Ovarian Cancer screening test (EXO-OC test); • Expedite preclinical studies for its high value CAR-Exosome therapeutic program for solid tumours; • Expand EXO-NET business and partner Su
Slide 40: Capital Raising | Placement & SPP
Capital Raising| Placement & SPP Event Date Trading halt commences Thursday, 9 October 2025 Placement opens 7pm (Sydney time) Record date for SPP Friday, 10 October 2025 Announcement of Placement and SPP Monday, 13 October 2025 Recommencement of trading Settlement of Placement Thursday, 16 October 2
Slide 41: Contacts
Contacts Dr Leearne Hinch BVMS MBA Prof Gregory Rice PhD MHA Chief Executive Officer Chief Scientific Officer e. lhinch@inoviq.com e. grice@inoviq.com Mark Edwards BAcc CA Dr Emma Ball PhD MBA GAICD CFO & Company Secretary Chief Commercial Officer e. medwards@inoviq.com e. eball@inoviq.com INOVIQ Lt
Slide 42: Appendices & Risks
Appendices & Risks =INOVIQ
Slide 43: Glossary
Glossary AUC area under the curve IVD in vitro diagnostic BC breast cancer KOL key opinion leader CA125 cancer antigen 125 biomarker (used in ovarian cancer) LDT laboratory developed test CA15-3 cancer antigen 15-3 biomarker (used in breast cancer) MIA in vitro multivariate index assay CAGR compound
Slide 44: Leadership
Leadership| Corporate, scientific, clinical and commercial expertise MANAGEMENT DR LEEARNE HINCH BVMS MBA PROF GREG RICE PhD MHA MARK EDWARDS BAcc CA EMMA BALL PhD MBA GAICD Chief Executive Officer Chief Scientific Officer CFO & Company Secretary Chief Commercial Officer Biotechnology CEO with a pro
Slide 45: Board
Board| Capital markets, healthcare and biotech experience DAVID WILLIAMS MAX JOHNSTON PHILIP POWELL Non-Executive Chairman Non-Executive Director Non-Executive Director Experienced biotechnology director and Healthcare industry director and Healthcare industry director and investment banker with ext
Slide 46: Strong IP portfolio covering technologies and applications
Strong IP portfolio covering technologies and applications Patent Family Title Granted Pending Expiry Molecular NETs PCT/US2010/058086 Devices for detection of analytes CN, US(cont1), US US(cont6) 2030 (WO2011/066449) (cont2), US(cont3) PCT/US2013/049779 Molecular Nets EP 2033 • 6 patent families wi
Slide 47: EXO-OC | Scalable, flexible workflow
EXO-OC | Scalable, flexible workflow Designed to integrate seamlessly with existing workflows and instruments in HT pathology labs EXO-NET RNA Data Analysis Sample Prep exosome RT-qPCR & Clinical report isolation extraction Interpretation Plasma 200μl for Exosome Biomarker Analysis of Fast RNA + CA-
Slide 48: CAR-Exosomes | Potential advantages over autologous CAR-T therapy
CAR-Exosomes| Potential advantages over autologous CAR-T therapy Off-the- • Next-gen cell-free therapy to target and kill solid tumours shelf, allogenic • Versatile and flexible technology platform with multiple Stabile & therapy Multiple therapeutic applications easier to therapeutic manufacture ap
Slide 49: References
References| Ovarian Cancer in 9 Major Markets 1. United Nations, Data Portal, Population Division, 2024 data 2. The Lancet, Volume 55, Special Issue 101426, February 2025 3. Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021, CDC, https://www.cdc.gov/pcd
Slide 50: References
References| Diagnostic & therapeutic deals Diagnostic deals| Liquid biopsy platforms 1. Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests, 6 August 2025 2. Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technolo
Slide 51: Key Risks
Key Risks This section includes details of the key risks attaching to an investment in INOVIQ securities. These risks may affect the future operating and financial performance of INOVIQ and the value of INOVIQ securities. Before deciding whether to invest in INOVIQ securities, you should consider wh
Slide 52: Key Risks (cont.)
Key Risks (cont.) SPECIFIC RISK DESCRIPTION There are general risks associated with investments in equity capital such as INOVIQ securities. The trading price of INOVIQ securities may fluctuate with movements in equity capital markets in Australia and internationally. There is no assurance that the
Slide 53: Key Risks (cont.)
Key Risks (cont.) SPECIFIC RISK DESCRIPTION It is likely that INOVIQ will need to form marketing and/or product development alliances with third parties for INOVIQ products in countries which INOVIQ seeks to commercialise (subject to ongoing legal and regulatory compliance and financial viability to
Slide 54: Key Risks (cont.)
Key Risks (cont.) SPECIFIC RISK DESCRIPTION The diagnostic and therapeutic industry is regulated in Australia, the United States, Europe and other countries in which INOVIQ may conduct business operations or seek to commercialise its products. INOVIQ has not yet formally engaged with the TGA (Austra
Slide 55: Key Risks (cont.)
Key Risks (cont.) GENERAL RISK DESCRIPTION INOVIQ securities are only listed on the securities exchange operated by ASX and will not be listed for trading on any other financial markets, other than Chi-X. There can be no guarantee that an active market in INOVIQ securities will continue. If an activ
Slide 56: Key Risks (cont.)
Key Risks (cont.) GENERAL RISK DESCRIPTION INOVIQ may be subject to significant unforeseen expenses or actions. This may include unplanned operating expenses, future legal actions or expenses in relation to future unforeseen events. Unforeseen expenses Whilst the company is not currently engaged in